Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

D. Lynn Kirkpatrick, Cari Evans, Linda A. Pestano, Jeffrey Millard, Matthew Johnston, Emily Mick, William K. Schmidt

Open source

DOI
10.1111/cts.13765
Published
2024-03
Container
Clinical and Translational Science
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/cts.13765,
  title = {Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers},
  author = {D. Lynn Kirkpatrick and Cari Evans and Linda A. Pestano and Jeffrey Millard and Matthew Johnston and Emily Mick and William K. Schmidt},
  year = {2024},
  journal = {Clinical and Translational Science},
  doi = {10.1111/cts.13765},
  url = {https://doi.org/10.1111/cts.13765}
}

RIS

TY  - JOUR
TI  - Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers
AU  - D. Lynn Kirkpatrick
AU  - Cari Evans
AU  - Linda A. Pestano
AU  - Jeffrey Millard
AU  - Matthew Johnston
AU  - Emily Mick
AU  - William K. Schmidt
PY  - 2024
JO  - Clinical and Translational Science
DO  - 10.1111/cts.13765
UR  - https://doi.org/10.1111/cts.13765
ER  - 

APA

Kirkpatrick, D. L., Evans, C., Pestano, L. A., Millard, J., Johnston, M., Mick, E., & Schmidt, W. K. (2024). Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers. Clinical and Translational Science. https://doi.org/10.1111/cts.13765

Source records